Oncopeptides Ab (Publ), A Biotech Company Focused On Research And Development Of Therapies For Difficult-To-Treat Haematological Diseases, Announces That Pepaxti (Melphalan Flufenamide, Also Called Melflufen) Has Been Granted Marketing Authorization In Combination With Dexamethasone, By The Medicines & Healthcare Products Regulatory Agency, Mhra, In Uk.
